Cutting-Edge Immunotherapy Offers New Hope for Glioblastoma Patients

Cutting-Edge Immunotherapy Offers New Hope for Glioblastoma Patients

Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system more effectively than traditional therapies, particularly against evasive and deadly glioblastoma tumors

MRI Study Shows Impact of Gross Total Resection on Survival of Patients with IDH Wild-Type Glioblastoma

Irrespective of age or O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, gross total resection of IDH wild-type glioblastomas was associated with a median overall survival of 32.6 months, according to new MRI research.